NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-22-057 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from early and mid-career investigators (i.e. postdoctoral fellow/associates associate professor) who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of therapeutic drug, biologic, or device development. The development of novel treatments for pain, addiction, and overdose is a vital component to address the ongoing opioid epidemic. This development will be most effective if performed by scientists with training in translational science. Translation is defined as the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and the public from diagnostics and therapeutics to medical procedures and behavioral changes, with translational science representing the field of investigation focused on understanding the scientific and operational principles underlying each step of the translational process (https://ncats.nih.gov/translation). Traditional academic training provides deep knowledge of a relatively narrow scientific discipline. While domain expertise is an important characteristic of a proficient translational scientist, a comprehensive understanding of the stages of therapeutic development is also necessary. For many trainees, acquiring needed expertise through participatory training in the various fields that are required to compile an investigational new drug (IND), investigational device exemption (IDE), or new drug application (NDA) is extraordinarily difficult given the diversity of these domains.
Funding Opportunity RFA-MD-22-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to develop a technology or product, process, or service for commercialization to improve, reduce, and eliminate health disparities in one or more NIH-defined population groups. Appropriate technologies should be effective, affordable, and culturally acceptable.
Funding Opportunity RFA-MD-22-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more NIH-defined populations experiencing health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable.
Funding Opportunity RFA-HL-23-003 from the NIH Guide for Grants and Contracts. The purpose of this limited competition R00 program is to provide physician scientists in blood science with a seamless pathway from a mentored K99/R00 award to investigator independence. Eligible applicants will have matriculated through the Career Pathway to Independence in Blood Science Awards for Physician Scientists ( K99/R00) program for up to three, but no more than five years. The strongest R00 applicants will propose an updated, well-conceived plan for 23 years of independent research support intended to prepare the applicant to subsequently compete for an R01 or equivalent award. These research projects are limited to those that fall within the Division of Blood Diseases and Resources mission. The NIH encourages institutions to recruit and retain individuals from groups currently underrepresented in the biomedical sciences, and to enhance the diversity of the clinician-investigator workforce (NOT-OD-15-053).
Funding Opportunity RFA-AG-23-008 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for pharmacokinetic and pharmacodynamic (PK/PD) studies of mTOR inhibitors inpopulations living with different aging-related diseases or in relatively healthy older adult populations at risk for a variety of aging conditions. The studies will be funded by individual awards but will be required to interact as a network to exchange information, possibly develop harmonized measures, and pool data to facilitate broader assessment of the effects on multiple aging-related outcomes and mechanisms affected by mTOR modulation.
Notice of Intent to Publish Funding Opportunity Announcements for the RADx-UP Initiative (Phase III)
Notice NOT-OD-22-051 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-363 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from qualified institutions to develop or renovate breeding and research space for basic, translational, clinical, and social/behavioral science research using non-human primates (NHPs). This FOA targets NHP facilities supported by NIH. Any request must be justified by current and anticipated future research needs.
Notice NOT-NS-22-052 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-043 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-040 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-056 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-050 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-088 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites qualified academic and research institutions to apply for funding to modernize existing or construct new biomedical research facilities. Applications will be accepted from public and private nonprofit institutions of higher education as well as from non-profit research organizations. Applications from both research-intensive institutions and Institutions of Emerging Excellence in biomedical research from all geographic regions in the nation are strongly encouraged. NIH recognizes the importance of all institutions of higher learning in contributing to the nations research capacity. The goal of this FOA is to upgrade or create novel biomedical research infrastructure to strengthen biomedical research programs. Each project is expected to provide long-term improvements to the institutional research infrastructure. Targeted projects are the construction or modernization of core facilities and the development of other infrastructure serving an institution-wide research community on a shared basis.
Funding Opportunity RFA-DK-21-020 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to establish a clinical consortium to determine the factors that contribute to the heterogeneity in the restoration of impaired awareness of hypoglycemia (IAH) and improved counter-regulatory responses in adult individuals with Type 1 Diabetes (T1D). Individuals with IAH are often excluded from clinical trials and this omission contributes greatly to a lack of knowledge regarding the clinical characteristics which determine or predict an individuals ability to restore hypoglycemic awareness. New technologies such as continuous glucose monitors (CGM) and closed loop systems (i.e. artificial pancreas) have been shown to reduce hypoglycemic events. However, despite a reduction in hypoglycemic events, restoration of hypoglycemia awareness does not occur in all individuals and the effects on improving the counter-regulatory responses are not known. The goals of the clinical consortium will be to 1) determine if state-of-the-art diabetes technology to optimize HbA1c while minimizing hypoglycemia can restore awareness of hypoglycemia and improve counter-regulatory responses in individuals with T1D; 2) identify the magnitude and duration of time in range (TIR), time spent in hypoglycemia or other CGM metrics that are associated with restoration of awareness of hypoglycemia; and 3) validate current self-report assessments of impaired awareness of hypoglycemia with physiological measurements. It is expected that state of the art techniques such as hypoglycemic, hyperinsulinemic clamps (with or without stable isotopes) for the measurement of counter-regulatory responses and endogenous glucose production will be utilized to determine restoration of awareness and validate self-report assessments.
Funding Opportunity RFA-DK-21-036 from the NIH Guide for Grants and Contracts. This FOA invites applications for a Biostatistics Research Center (BRC) to participate in a clinical consortium to determine the factors that contribute to the heterogeneity in the restoration of impaired awareness of hypoglycemia (IAH) and improved counter-regulatory responses in adult individuals with Type 1 Diabetes (T1D) and impaired awareness of hypoglycemia (IAH). A separate FOA (RFA-DK-21-020) invites Clinical Centers to 1) determine if the most up-to-date diabetes technology to optimize HbA1c while minimizing hypoglycemia can restore awareness of hypoglycemia and improve counter-regulatory responses in individuals with T1D and IAH; 2) identify the magnitude and duration of time in range (TIR), time spent in hypoglycemia or other CGM metrics that are associated with restoration of awareness of hypoglycemia; and 3) validate current self-report assessments of impaired awareness of hypoglycemia with physiological measurements derived from state of the art metabolic assessments.
Notice NOT-MH-22-105 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-22-171 from the NIH Guide for Grants and Contracts. Efforts are underway to develop a safe and effective vaccine to protect people from acquiring HIV ultimately reducing the number of new infections and ending the epidemic. However, the subject of vaccines remains contentious, and COVID-19 has heightened the conversation. There are multiple messages circulating both for and against vaccines and a growing number of skeptics appear to be making decisions about vaccines based on misinformation. This initiative will advance research on communication factors and strategies that will be crucial for successful public understanding, acceptance, and uptake of future vaccines that protect against HIV.
Funding Opportunity RFA-MH-22-170 from the NIH Guide for Grants and Contracts. Efforts are underway to develop a safe and effective vaccine to protect people from acquiring HIV ultimately reducing the number of new infections and ending the epidemic. However, the subject of vaccines remains contentious, and COVID-19 has heightened the conversation. There are multiple messages circulating both for and against vaccines and a growing number of skeptics appear to be making decisions about vaccines based on misinformation. This initiative will advance research on communication factors and strategies that will be crucial for successful public understanding, acceptance, and uptake of future vaccines that protect against HIV.
Funding Opportunity RFA-DA-22-049 from the NIH Guide for Grants and Contracts. This FOA seeks applications for one Modeling and Economic Resource Center to support the HEAL D2A Innovation Projects. This center will provide expertise in a variety of simulation modeling and economic analyses and methods; utilize agent-based, predictive, geospatial or other simulation models to inform Innovation Project grantees about the potential public health impact of implementing different interventions, to support local implementation decisions; support the Innovation Projects in assessing costs and cost benefit associated with selected service delivery changes; develop costing tools that can be utilized by Innovation Grants to inform local decisions about the selection of interventions; and conduct original research applying state-of-the-art economic and simulation modeling expertise to understand and address the overdose crisis. This FOA runs in parallel with a set of companion FOAs supporting the other components of the HEAL D2A Program.
Funding Opportunity RFA-DA-22-050 from the NIH Guide for Grants and Contracts. This FOA solicits applications for one HEAL D2A Research Adoption Support Center to provide coordination and implementation support for the HEAL D2A Innovation Projects. The Centers primary purpose is to support funded projects in the selection and deployment of evidence-based practices to address identified needs. The Research Adoption Support Center will also provide logistical coordination for the initiative, engage key stakeholders, conduct rapid-turnaround studies in response to stakeholder-identified priorities, and conduct a formative evaluation of the HEAL D2A Program. This FOA runs in parallel with a set of companion FOAs supporting the other components of the HEAL D2A Program.